J&J innovative medicine, solid tumours and clinical development vice-president Kiran Patel stated: “We are redefining care for patients with non-small cell lung cancer by advancing innovative ...

J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them," noted Bill Martin, J&J Innovative Medicine's ...

J&J’s Innovative Medicine unit is showing a growing trend. The segment’s sales rose 5.8% in 2024 on an organic basis. In 2025, J&J expects growth in the Innovative Medicine segment despite the ...

Kevin Hamill, President, U.S. Immunology, Johnson & Johnson Innovative Medicine ... “As a company, J&J is committed to leading where medicine is going,” Hamill says.

However, this figure represents an almost 11% decline from the previous year. Furthermore, J&J's innovative medicine unit generated $14.33 billion in sales, while its medtech unit reached $8.19 ...

Picture: Darragh Kane Pharmaceutical giant Johnson & Johnson Innovative Medicine (J&J IM) was named Company of the Year at Cork Chamber’s annual dinner in Cork City Hall on Friday. The company ...

It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism ...

The deal provides J&J with an FDA-approved atypical antipsychotic ... “This unique opportunity to add Intra-Cellular Therapies to our Innovative Medicine business demonstrates our commitment ...

The PhRMA Foundation announced the appointment to its Board of Directors of Dr. John C. Reed, MD, PhD, Executive Vice President of Innovative Medicine R&D at Johnson & Johnson (J&J), and Dr. Donatello ...